Tonix Pharmaceuticals Holding Corp. — Form 8-K
Reporting/event date: October 1, 2026; signed October 2, 2026. This current report describes a patent notice concerning TONMYA, not a quarterly or annual financial report.
Business context and material development
Tonix received notice from Dr. Reddy’s Laboratories Ltd. and Dr. Reddy’s Laboratories, Inc. that they filed an ANDA with the FDA seeking approval for a generic version of TONMYA (cyclobenzaprine hydrochloride) sublingual tablets, 2.8 mg. The ANDA includes a Paragraph IV certification challenging four TONMYA patents listed in the FDA Orange Book: U.S. Patent Nos. 9,636,408; 9,956,188; 10,117,936; and 10,864,175.
Tonix says it intends to vigorously enforce its intellectual property rights, but cannot predict the outcome of the matter or any litigation. The filing does not report a lawsuit filing, an FDA decision, or a change in TONMYA’s commercial status.
Financial metrics and comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating results, and no comparable-period figures. The filing does not provide a clear value for TONMYA sales or the potential financial impact of generic competition.
Outlook, legal process, and risks
According to the filing, a patent infringement lawsuit filed within 45 days after receipt of the Paragraph IV notice would prevent FDA approval of the ANDA until the earliest of specified events. These include expiration of a 30-month period beginning when the patent owner receives the notice, patent expiration, certain settlement or court outcomes, or a different period ordered by the court. The filing does not say that this stay has been triggered.
Risks identified include adverse litigation outcomes; patents being found invalid, unenforceable, or not infringed; FDA approval of this or other generic applications; litigation costs and management distraction; and the effect of generic competition on TONMYA sales. Tonix cautions that outcomes and timing are uncertain and disclaims an obligation to update forward-looking statements.
Key facts for investors to verify
- Whether and when Tonix files an infringement lawsuit within the applicable 45-day period.
- The status and outcome of any litigation, including rulings on the four Orange Book patents.
- FDA review and any approval of DRL’s ANDA or other generic applications.
- TONMYA sales exposure and any subsequent company disclosure quantifying the impact of generic competition or litigation.